EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells
Open accessPublished version of a preprint
Abstract
Abstract Enhancer of zeste homolog (EZH2) is a key epigenetic regulator of gene expression and is frequently overexpressed in various cancer types, suggesting a role in oncogenesis. The therapeutic potential of EZH2 inhibitors is currently being explored, but their effect on antitumor immunity is largely unknown. Here we report that suppressing EZH2 activity using EZH2 inhibitor GSK126 resulted in increased numbers of myeloid-derived suppressor cells (MDSC) and fewer CD4+ and IFNγ+CD8+ T cells, which are involved in antitumor immunity. Addition of a neutralizing antibody against the myeloid differentiation antigen GR-1 or gemcitabine/5-fluorouracil–depleted MDSCs alleviated MDSC-mediated immunosuppression and increased CD4+ and CD8+ T-cell tumor infiltration and GSK126 therapeutic efficacy. Mechanistically, we identified a novel pathway of MDSC production in cancer in which EZH2 inhibition directs myeloid differentiation from primitive hematopoietic progenitor cells. These findings suggest that modulating the tumor immune microenvironment may improve the efficacy of EZH2 inhibitors. Significance: This study uncovers a potential mechanism behind disappointing results of a phase I clinical trial of EZH2 inhibitor GSK126 and identifies a translatable combinational strategy to overcome it.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The EZH2 inhibitor GSK126 promotes MDSC expansion and immunosuppressive functions.
“EZH2 inhibition with GSK126 reportedly favors MDSC expansion and immunosuppressive functions”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Huang et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515 · see citing works
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · see citing works
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · see citing works
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · see citing works
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245 · see citing works
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works
Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors
Paul, F., Arkin, Y., Giladi, A., Jaitin, D. A., Kenigsberg, E., Keren-Shaul, H., Winter, D., Lara-Astiaso, D., Gury, M., Weiner, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.013 · Cited by 1,082 · see citing works
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M. F., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 877 · see citing works
Béguelin, W., Popovic, R., Teater, M. R., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 854 · see citing works
Kim, E. H., Kim, M., Woo, D., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 811 · see citing works
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Гарипов, А. Р., Li, H., Amatangelo, M. D., Kossenkov, A. V., Schultz, D., Liu, Q., Shih, I., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 683 · see citing works
Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., Márquez, V. E., & Jones, P. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0013 · Cited by 588 · see citing works
Chase, A., & Cross, N. C. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2156 · Cited by 548 · see citing works
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535 · see citing works
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S. R., Pratt, B. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 533 · see citing works
Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., Vatan, L., et al. (2016) · Nature Immunology · doi:10.1038/ni.3313 · Cited by 405 · see citing works
Self-citationDuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332 · see citing works
Tumes, D. J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C., Hosokawa, H., Koseki, H., Tokoyoda, K., Suzuki, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.09.012 · Cited by 291 · see citing works
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T. L., Vatan, L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 270 · see citing works
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Brainson, C. F., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Márquez, V. E., Hammerman, P. S., Wong, K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255 · see citing works
Enhancer of zeste homolog 2 (EZH2) inhibitors
Gulati, N., Béguelin, W., & Giulino-Roth, L. G. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 196 · see citing works
Gunawan, M., Venkatesan, N., Loh, J. T., Wong, J. F., Berger, H., Neo, W. H., Li, J. L. Y., Win, M. K. L., Yau, Y. H., Guo, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3125 · Cited by 185 · see citing works
van Deventer, H. W., Burgents, J. E., Wu, Q. P., Woodford, R.-M. T., Brickey, W. J., Allen, I. C., McElvania-Tekippe, E., Serody, J. S., & Ting, J. P.-Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1921 · Cited by 172 · see citing works
Yin, J., Leavenworth, J. W., Li, Y., Luo, Q., Xie, H., Liu, X., Huang, S., Yan, H., Fu, Z., Zhang, L. Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521740112 · Cited by 169 · see citing works
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
Crea, F., Fornaro, L., Bocci, G., Sun, L., Farrar, W. L., Falcone, A., & Danesi, R. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9387-3 · Cited by 164 · see citing works
EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion
Yang, X., Jiang, K., Hirahara, K., Vahedi, G., Afzali, B., Sciumè, G., Bonelli, M. M., Sun, H., Jankovic, D. L., Kanno, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep10643 · Cited by 154 · see citing works
Kawano, M., Mabuchi, S., Matsumoto, Y., Sasano, T., Takahashi, R., Kuroda, H., Kozasa, K., Hashimoto, K., Isobe, A., Sawada, K., et al. (2015) · Scientific Reports · doi:10.1038/srep18217 · Cited by 145 · see citing works
He, S., Liu, Y., Meng, L., Sun, H., Wang, Y., Ji, Y., Purushe, J., Chen, P., Li, C., Madžo, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02187-8 · Cited by 129 · see citing works
EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer
Geng, J., Li, X., Zhou, Z., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.031 · Cited by 109 · see citing works
EZH2 in normal hematopoiesis and hematological malignancies
Herviou, L., Cavalli, G., Cartron, G., Klein, B., & Moreaux, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6198 · Cited by 106 · see citing works
EZH2 as a potential target in cancer therapy
McCabe, M. T., & Creasy, C. L. (2014) · Epigenomics · doi:10.2217/epi.14.23 · Cited by 89 · see citing works
Kodach, L. L., Jacobs, R. J., Heijmans, J., van Noesel, C. J. M., Langers, A. M. J., Verspaget, H. W., Hommes, D. W., Offerhaus, G. J. A., BRINK, G. R. V. D., & Hardwick, J. C. H. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq147 · Cited by 81 · see citing works
Regulation of T Cell Differentiation and Function by EZH2
Karantanos, T., Chistofides, A., Barhdan, K., Li, L., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00172 · Cited by 81 · see citing works
C/EBPϵ interacts with retinoblastoma and E2F1 during granulopoiesis
Gery, S., Gombart, A. F., Fung, Y. K., & Koeffler, H. P. (2003) · Blood · doi:10.1182/blood-2003-01-0159 · Cited by 63 · see citing works
RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo
Chen, Y., Xie, D., Li, W. Y., Cheung, C. M., Yao, H., Chan, C. Y., Chan, C., Xu, F.-P., Liu, Y. H., Sung, J. J. �., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.05.003 · Cited by 63 · see citing works
Chen, G., Subedi, K., Chakraborty, S., Sharov, A. A., Lü, J., Kim, J., Mi, X., Wersto, R. P., Sung, M., & Weng, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00549 · Cited by 56 · see citing works
Xia, S., Li, X., Cheng, L., Han, M., Zhang, M., Liu, X., Xu, H., Zhang, M., Shao, Q., & Qi, L. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1546-7 · Cited by 20 · see citing works
Will we be able to afford a cure in multiple myeloma?
Chakraborty, R., & Gertz, M. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339883 · Cited by 18 · see citing works
Kim, K., Hwang, S. M., Kim, S. M., Park, S. W., Jung, Y., & Chung, I. Y. (2017) · Immune Network · doi:10.4110/in.2017.17.6.410 · Cited by 14 · see citing works
LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBPε in granulocytes
Suh, H. C., Benoukraf, T., Shyamsunder, P., Tong, Y., Cao, Q., SAID, J. W., Lee, S., Lim, R., Yang, H. H., Salotti, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46440 · Cited by 9 · see citing works
Flagged first, then by citations
2 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 946 · see citing works
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934 · see citing works
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W. T., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 404 · see citing works
“GSK126 was also found to be associated with increased nfiltration MDSCs and fewer CD4 and IFNγCD8 T cells.(396) Muscle-invasive bladder cancer cells with KMD6A and SWI/SNF mutations were more sensitive to an EZH2 inhibitor (EPZ011989), which is mediated by enhanced NK cell-related signaling, resulting in tumor cell di…”
BackgroundEpigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 332 · see citing works
“Finally, inhibition of EZH2 by GSK126 has been shown to suppress antitumor immunity by reinforcing MDSC content in tumors [140].”
BackgroundCancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 297 · see citing works
“Treatment with GSK126 (an EZH2 inhibitor) inhibits the growth of immune-de fi cient tumor cells [114].”
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 287 · see citing works
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 246 · see citing works
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Неганова, М. Е., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 203 · see citing works
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Xiao, G., Jin, L.-L., Liu, C., Wang, Y., Meng, Y.-M., Zhou, Z., Chen, J., Yu, X.-J., Zhang, Y., Xu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0784-9 · Cited by 182 · see citing works
The role of epigenetic modifications in drug resistance and treatment of breast cancer
Fath, M. K., Azargoonjahromi, A., Kiani, A., Jalalifar, F., Osati, P., Oryani, M. A., Shakeri, F., Nasirzadeh, F., Khalesi, B., Nabi‐Afjadi, M., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00344-6 · Cited by 151 · see citing works
Chen, Y., Ren, B., Yang, J., Wang, H., Yang, G., Xu, R., You, L., & Zhao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00252-1 · Cited by 143 · see citing works
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 108 · see citing works
Myeloid-Derived Suppressor Cells in Solid Tumors
Ma, T., Renz, B. W., Ilmer, M., Koch, D. T., Yang, Y., Werner, J., & Bazhin, A. V. (2022) · Cells · doi:10.3390/cells11020310 · Cited by 110 · see citing works
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Li, B., & Chng, W. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0814-6 · Cited by 99 · see citing works
“gative mediation of anti-tumor immunity [161].”
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94 · see citing works
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 87 · see citing works
Immune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 83 · see citing works
“While inhibition of the methyltransferase EZH2 can recover HLA class I APM expression in different tumor types [54] and has also been demonstrated to “repolarize” Treg [67], it can also induce the expansion of myeloid-derived suppressor cells (MDSC), thus possibly nullifying its positive effect [68].”
BackgroundEZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation
Song, S., Zhang, R., Mo, B., Chen, L., Liu, L., Yu, Y., Cao, W., Fang, G., Wan, Y., Gu, Y., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.08.003 · Cited by 82 · see citing works
Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy
Zhang, S., Meng, Y., Zhou, L., Qiu, L., Wang, H., Su, D., Zhang, B., Chan, K. M., & Han, J. (2022) · MedComm · doi:10.1002/mco2.173 · Cited by 82 · see citing works
Sun, S., Feng, Y., Xu, D., Zheng, H., & Li, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188700 · Cited by 77 · see citing works
Wang, Y., Lei, Y., Hu, Z.-L., Fang, Y.-F., Shen, Y., Song, M., & Chen, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05169-x · Cited by 80 · see citing works
“Suppressing EZH2 activity by EZH2 inhibitor GSK126 resulted in more myeloid-derived suppressor cells (MDSC) and less CD4 and IFNγCD8 T cells accumulated in tumors, which are key components of anti-tumor immunity, suggesting that EZH2 inhibitors may exhibit antitumor efficacy by modulating tumor immune microenvironment…”
BackgroundLi, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 77 · see citing works
“Therefore, the combination of GSK126 and MDSC-suppressors, such as anti-Gr1 antibody and gemcitabine/5-fluorouracil, can improve the anti-tumor ability of the treatment and overcome the deficiency of EZH2i [48].”
BackgroundTumor-associated myeloid cells in cancer immunotherapy
Cheng, X., Wang, H., Wang, Z., Zhu, B., & Long, H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01473-x · Cited by 75 · see citing works
“In addition, gemcitabine/5-FU can reduce immunosuppression by depleting MDSCs and increasing the intratumoral infiltration of CD4+ and CD8+ T cells [118].”
BackgroundLi, C., Song, J., Guo, Z., Gong, Y., Zhang, T., Huang, J., Cheng, R., Yu, X., Li, Y., Chen, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857808 · Cited by 68 · see citing works
“Moreover, suppressing EZH2 activity by GSK126 increased myeloid-derived suppressor cells (MDSCs) and consequent suppression of anti-tumor immunity (6).”
BackgroundResultInfluentialComposite Hydrogel for Spatiotemporal Lipid Intervention of Tumor Milieu
Ma, J., Guo, D., Ji, X., Zhou, Y., Liu, C., Li, Q., Zhang, J., Fan, C., & Song, H. (2023) · Advanced Materials · doi:10.1002/adma.202211579 · Cited by 65 · see citing works
Amin, R., Shukla, A., Zhu, J. J., Kim, S., Wang, P., Tian, S. Z., Tran, A. D., Paul, D., Cappell, S. D., Burkett, S. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27451-w · Cited by 62 · see citing works
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Wang, Y., Jia, A., Bi, Y., Wang, Y., Yang, Q., Cao, Y., Li, Y., & Liu, G. (2020) · Cancers · doi:10.3390/cancers12092626 · Cited by 63 · see citing works
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior
Kumar, V. E., Nambiar, R., Souza, C. D., Nguyen, A. D., CHIEN, J. R., & Lam, K. S. (2022) · Cells · doi:10.3390/cells11091403 · Cited by 59 · see citing works
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Wang, B., Liu, Y., Liao, Z., Wu, H., Zhang, B., & Zhang, L. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00405-2 · Cited by 57 · see citing works
“Xenograft models also showed good antitumor effects, however, GSK126 was found to negatively affect antitumor immunity by increasing MDSCs and decreasing the number of CD4+ and IFNγ+ CD8+ T cells [73, 74].”
BackgroundHan, X., Shi, H., Sun, Y., Shang, C., Luan, T., Wang, D., Ba, X., & Zeng, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1837-1 · Cited by 56 · see citing works
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy
Sanctis, F. D., Adamo, A., Canè, S., & Ugel, S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00965-1 · Cited by 54 · see citing works
“EZH2 inhibition, a histone-lysine N-methyltransferase, has reported to suppress anti-tumour immunity by driving MDSC differentiation from primitive hematopoietic progenitors reducing CD4+ and IFNγ+CD8+ T cells in lung and colon carcinoma models [80].”
BackgroundCrosstalk Between Inflammatory Signaling and Methylation in Cancer
Das, D., Karthik, N., & Taneja, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.756458 · Cited by 54 · see citing works
Lysine methyltransferase inhibitors: where we are now
Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 48 · see citing works
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 49 · see citing works
“There is some evidence for contrary results, such as the MDSC-promoting and Teff cell-inhibiting effects of EZH2 inhibitor GSK126 reported in a study [295].”
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)
Dockerill, M., Gregson, C. L., & O’Donovan, D. H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841167 · Cited by 46 · see citing works
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 43 · see citing works
“GSK126 inhibited EZH2 and simultaneously promoted the development of MDSCs [138, 139].”
Greer, C. B., Wright, J., Weiss, J. D., Lazarenko, R. M., Moran, S. P., Zhu, J., Chronister, K. S., Jin, A., Kennedy, A. J., Sweatt, J. D., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1821-20.2020 · Cited by 41 · see citing works
“To test whether H3K27me3-mediated silencing accounted for differences in Tet1 expression between glia and neurons, we blocked formation of the repressive mark using the two histone-lysine N-methyltransferase Enhancer of Zeste Homolog 2 (EZH2) inhibitors, GSK126 and GSK343 (Verma et al., 2012; Huang et al., 2019).”
MethodAdvances in Epigenetic Cancer Therapeutics
Hillyar, C., Rallis, K. S., & Varghese, J. S. (2020) · Cureus · doi:10.7759/cureus.11725 · Cited by 40 · see citing works
“GSK126 reduces anti-tumour immunity by increasing the number of myeloid-derived suppressor cells, leading to fewer CD4+ and CD8+ T cells in the tumour microenvironment [28].”
BackgroundEzh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation
Yuan, J., Zhu, Q., Zhang, X., Wen, Z., Zhang, G., Li, N., Pei, Y., Wang, Y., Pei, S., Xu, J., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00992-3 · Cited by 37 · see citing works
“Targeting SETmediated methyltransferase activity through the selective inhibitor GSK126 has been applied in clinical trials for the treatment of patients with multiple types of tumours [14, 42, 43].”
EZH2: An Accomplice of Gastric Cancer
Yu, W., Liu, N., Song, X., Chen, L., Wang, M., Xiao, G., Li, T., Wang, Z., & Zhang, Y. (2023) · Cancers · doi:10.3390/cancers15020425 · Cited by 37 · see citing works
“In another study, however, GSK126 exerted anti-tumor activity in immunologically active hosts combined with drugs (gemcitabine and 5-fluorouracil) that deplete myeloid-derived suppressor cells [104].”
BackgroundLi, L., Zhang, H., Zhou, Z., Duan, L., Fan, D., Wang, R., Xu, S., Qiao, D., & Zhu, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116470 · Cited by 37 · see citing works
EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer
Chen, Y., Zhu, H., Luo, Y., Tong, S., & Liu, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116624 · Cited by 35 · see citing works
Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases
Yang, Y., Luan, Y., Luan, Y., & Luan, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.710053 · Cited by 34 · see citing works
“Among these inhibitors, GSK126 is a potent and highly selective methyltransferase inhibitor for the histone methyltransferase EZH2 [Figure 4; (143)].”
BackgroundEZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma
Xu, T., Dai, J., Tang, L., Yang, L., Si, L., Sheng, X., Cui, C., Chi, Z., Kong, Y., & Guo, J. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.08.437 · Cited by 34 · see citing works
Huang, J., Zhang, J., Guo, Z., Li, C., Tan, Z. W., Wang, J., Yang, J., & Xue, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741302 · Cited by 32 · see citing works
Uceda, S., Echeverry‐Alzate, V., Reiriz, M., Miguel, E. M., Pérez-Curiel, A., Gómez-Senent, S., & Beltrán-Velasco, A. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713294 · Cited by 35 · see citing works
Liu, W., Kuang, T., Liu, L., & Deng, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407449 · Cited by 32 · see citing works
The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer
Zhang, Y., Zhang, Q., Zhang, Y., & Han, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054939 · Cited by 32 · see citing works
Hou, Y., Žák, J., Shi, Y., Pratumchai, I., Dinner, B., Wang, W., Qin, K., Weber, E. W., Teijaro, J. R., & Wu, P. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0089 · Cited by 31 · see citing works
Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease
Cai, Q., Gan, C., Tang, C., Wu, H. M., & Gao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.784591 · Cited by 30 · see citing works
“…Methylates histone H3K36 and H3K4 — Perugorria et al. (2012) EZH2 4MI5 Methylates histone H3K27 Tazemetostat; Valemetostat, GSK126, CPI0209, CPI-1205 Huang et al. (2019), Bates (2020) SETDB1 3DLM Methylates histone H3K9 Mithramycin, DZNep Rivière et al. (2015), Karanth et al. (2017) MLL4/KMT2D,…”
Polycomb Directed Cell Fate Decisions in Development and Cancer
German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 36 · see citing works
“Interestingly, the depletion of MDSCs in TME promotes antitumor immune responses through the increased infiltration of functional T-cells [245].”
BackgroundLiu, Q., Yu, M., Lin, Z., Wu, L., Xia, P., Zhu, M., Huang, B., Wu, W., Zhang, R., Li, K., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217731 · Cited by 30 · see citing works
Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 29 · see citing works
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
Ratnam, N. M., Sonnemann, H. M., Frederico, S. C., Chen, H. A., Hutchinson, M.-K. N. D., Dowdy, T., Reid, C. M., Jung, J., Zhang, W., Song, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719091 · Cited by 28 · see citing works
Hegde, M., Kumar, A., Girisa, S., Alqahtani, M. S., Abbas, M. A. E., Goel, A., Hui, K. M., Sethi, G., & Kunnumakkara, A. B. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.06.001 · Cited by 28 · see citing works
Chemical biology and pharmacology of histone lysine methylation inhibitors
Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 27 · see citing works
Lanzi, C., Arrighetti, N., Pasquali, S., & Cassinelli, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115727 · Cited by 27 · see citing works
Al‐Ghabkari, A., & Narendran, A. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1902913 · Cited by 26 · see citing works
“cytotoxic activity of a panel of EZH2-selcetive inhibitors; GSK343 [37], DZNep [38], GSK126 [39], EI1 [40], EPZ-5687 [41], UNC1999 [42], EPZ-6438 [43], and GSK503 [44].”
Maher, N., Maiellaro, F., Ghanej, J., Rasi, S., Moia, R., & Gaïdano, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178132 · Cited by 25 · see citing works
“For instance, GSK126, despite its strong preclinical activity against mutant EZH2 , failed to show meaningful clinical responses in a phase I trial in R/R DLBCL, transformed FL, and other NHL, leading to early trial termination [139,140].”
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 25 · see citing works
“The inhibition of the H3K27me3 HMT EZH2 using GSK126 increased the presence of MDSC within the TME of LLC (Lewis FIGURE 2 | Epigenetic factors that regulate TADC activity.”
BackgroundSunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC
Liu, J., Lin, W., Su, W., Wu, Z., Yang, Q., Wang, S., Sun, T.-G., Huang, C., Wang, X., & Sun, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110243 · Cited by 25 · see citing works
Xiao, C., Fan, T. T., Zheng, Y., Tian, H., Deng, Z., Liu, J., Li, C., & He, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005693 · Cited by 25 · see citing works
The functions of EZH2 in immune cells: Principles for novel immunotherapies
Shao, F.-F., Chen, B.-J., & Wu, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ru0520-311r · Cited by 23 · see citing works
Mola, S., Pinton, G., Erreni, M., Corazzari, M., Andrea, M. D., Grolla, A. A., Martini, V., Moro, L., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094391 · Cited by 25 · see citing works
“Inhibition of EZH2 has been reported to be linked with enhanced NK and T cell effector activities in certain cancers [25], as well as with an increased expansion of myeloid-derived suppressor cells (MDSCs) and consequent suppression of antitumor immunity [44].”
BackgroundEZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine
Barazeghi, E., Hellman, P., Norlén, O., Westin, G., & Stalberg, P. L. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-02181-7 · Cited by 23 · see citing works
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Zwergel, C., Fioravanti, R., & Mai, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103435 · Cited by 23 · see citing works
Liu, K., Li, Y., Shen, M., Xu, W., Wu, S., Yang, X., Zhang, B., & Lin, N. (2025) · Biomolecules · doi:10.3390/biom15010071 · Cited by 23 · see citing works
“The EZH2 inhibitor GSK126 was reported to direct myeloid differentiation and resulted in MDSC accumulation and TIL exclusion in syngeneic mouse models of lung cancers and colon cancer [161].”
Xiao, L., Zhou, Z., Li, W., et al. (2019) · Aging · doi:10.18632/aging.102241 · Cited by 22 · see citing works
Treating human cancer by targeting EZH2
Xu, M., Xu, C., Wang, R., Tang, Q., Zhou, Q., Wu, W., Wan, X., Mo, H., Pan, J., & Wang, S. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101313 · Cited by 22 · see citing works
“…anti-tumor effect than EZH2 selective inhibitor 114 ; gemcitabine/5-fluorouracil plus GSK126 combination therapy improves the efficacy of GSK126 and blocks tumor growth 117 ; combined anti-C-C motif chemokine ligand 2 therapy may improve the efficacy of EZH2 inhibitors in breast cancer treatment.”
Regulation of histone H3K27 methylation in inflammation and cancer
Ma, J., Zhang, Y., Li, J., Dang, Y., & Hu, D. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00254-x · Cited by 25 · see citing works
“GSK126, an EZH2 inhibitor, induced MDSC production and suppressed T-cell-mediated tumor immunity, masking its tumor-suppressing effects [149].”
Prognostic Value of EZH2 in Non‐Small‐Cell Lung Cancers: A Meta‐Analysis and Bioinformatics Analysis
Fan, K., Zhang, C., Qi, Y., Dai, X., Birling, Y., Tan, Z., & Cao, F. (2020) · BioMed Research International · doi:10.1155/2020/2380124 · Cited by 21 · see citing works
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20 · see citing works
Fischetti, I., Botti, L., Sulsenti, R., Cancila, V., Enriquez, C., Ferri, R., Bregni, M., Crivelli, F., Tripodo, C., Colombo, M. P., et al. (2024) · Epigenomics · doi:10.2217/epi-2023-0374 · Cited by 20 · see citing works
“Thus, our data do not contradict the findings from the paper of Huang et al. [25] , which tested GSK-126 as a single agent (showing that only doses higher than 50 mg / Kg have antitumor activity).”
BackgroundResultThe Adhesome Network: Key Components Shaping the Tumour Stroma
Nikolopoulou, P., Koufaki, M. A., & Kostourou, V. (2021) · Cancers · doi:10.3390/cancers13030525 · Cited by 21 · see citing works
“Interestingly, a recent study showed that Ezh2 inhibition in mice increased the number of immunosuppressive CD11b+Gr1+ cells within subcutaneous tumours [252].”
BackgroundEZH2 regulatory roles in cancer immunity and immunotherapy
Mortezaee, K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155992 · Cited by 20 · see citing works
AI‐Assisted Drug Re‐Purposing for Human Liver Fibrosis
Guan, Y., Cui, L., Inchai, J., Fang, Z., Law, J., Brito, A. A. G., Pawlosky, A., Gottweis, J., Daryin, A., Myaskovsky, A., et al. (2025) · Advanced Science · doi:10.1002/advs.202508751 · Cited by 19 · see citing works
Yang, J. C., Weisberg, E., Qi, S., Wei Min, N. I., Mei, H., Wang, Z., Meng, C., Zhang, S., Hou, M., Qi, Z., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01494-w · Cited by 19 · see citing works
Obesity-associated epigenetic alterations and the obesity-breast cancer axis
Lagarde, C. B., Kavalakatt, J., Benz, M. C., Hawes, M. L., Arbogast, C. A., Cullen, N. M., McConnell, E. C., Rinderle, C. H., Hebert, K. L., Khosla, M., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02954-0 · Cited by 19 · see citing works
“Interestingly, treatment with selective EZH2 inhibitors promoted M2 TAM in fi ltration and suppressed anti-tumor immune responses [96, 97].”
He, L., Liao, L., & Du, L. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4638 · Cited by 19 · see citing works
“In addition, inhibition experiments were performed using the EZH2 inhibitor, GSK126 (a compound competes with S-adenosyl-methionine for binding to EZH2, thereby inhibiting histone methyltransferase activity without affecting EZH2 protein expression), as previously described (16).”
MethodWu, L., Xu, Y., Zhao, H., Zhou, Y. J., Chen, Y., Yang, S., Lei, J., Zhang, J., Wang, J., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.66575 · Cited by 18 · see citing works
“Multiple evidence indicates that depletion of MDSCs by treatment with anti-Gr-1 neutralizing antibody or gemcitabine can restore immune surveillance and improve the efficacy of cancer immunotherapies in vivo [10, 34].”
BackgroundCui, H., Lan, Z., Zou, K., Zhao, Y., & Yu, G. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03336-9 · Cited by 18 · see citing works
Tan, L., Qin, Y., Xie, R., Xia, T., Duan, X., Peng, L., You, R., Liu, Y., Zou, X., Zhang, M., et al. (2022) · Theranostics · doi:10.7150/thno.76689 · Cited by 18 · see citing works
“The previous study has shown that suppressing EZH2 activity resulted in increased numbers of myeloid-derived suppressor cells (MDSC) and fewer CD4+ and IFNγ+CD8+ T cells, which are involved in antitumor immunity [40].”
BackgroundPickles, O. J., Wanigasooriya, K., Ptasinska, A., Patel, A. J., Robbins, H. L., Bryer, C., Whalley, C., Tee, L. J., Lal, N., Pinna, C. M. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0091 · Cited by 18 · see citing works
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Urbanova, M., Cihova, M., Buociková, V., Slopovský, J., Dubovan, P., Pinďák, D., Tomáš, M., García‐Bermejo, L., Rodríguez-Garrote, M., Earl, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115179 · Cited by 18 · see citing works
The Growing Relevance of Immunoregulation in Pediatric Brain Tumors
Melcher, V., & Kerl, K. (2021) · Cancers · doi:10.3390/cancers13225601 · Cited by 17 · see citing works
“This epigenetic intervention restrained tumor growth in immunocompromised mice but not in immunocompetent mice [94].”
BackgroundMxi1 participates in the progression of lung cancer via the microRNA-300/KLF9/GADD34 Axis
Lei, Y., Huang, Y., Lin, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04778-w · Cited by 17 · see citing works
“It has been previously noted that depletion of MDSCs is able to alleviate MDSC-mediated immunosuppression [36].”
BackgroundCombining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
Huang, R., Wu, Y., & Zou, Z. (2022) · Epigenomics · doi:10.2217/epi-2022-0320 · Cited by 17 · see citing works
Sylvestre, M., Tarte, K., & Roulois, D. (2019) · Epigenomics · doi:10.2217/epi-2019-0165 · Cited by 17 · see citing works
Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
Bleve, A., Consonni, F. M., Porta, C., Garlatti, V., & Sica, A. (2022) · Cancers · doi:10.3390/cancers14030510 · Cited by 17 · see citing works
Fan, K., Zhang, B.-H., Deng, H., & Sun, Y.-C. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05271-7 · Cited by 16 · see citing works
“The increased efficacy of anti-CTLA-4 immunotherapy and enhanced overall survival in tumor models of syngeneic mice [58, 59].”
BackgroundHistone Modifications and Their Targeting in Lymphoid Malignancies
Fernández-Serrano, M., Winkler, R., Santos, J. C., Pannérer, M.-M. L., Buschbeck, M., & Roué, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010253 · Cited by 14 · see citing works
“More recently, two orally bioavailable EZH1/2 dual inhibitors, (R)-OR-S1 and (R)-OR-S2, demonstrated improved antitumor activity in in vitro and in vivo models of EZH2MUT DLBCL with no significant toxicity [199].”
BackgroundInfluentialCombinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
Lee, Y.-T., Chuang, Y., & Chan, M. W. Y. (2020) · Epigenomes · doi:10.3390/epigenomes4040027 · Cited by 16 · see citing works
“reported that suppressing EZH2 activity promotes hematopoietic progenitor cell differentiation to myeloid-derived suppressor cells (MDSCs), and increases MDSCs in the tumor microenvironment, thus suppressing antitumor immunity [89].”
BackgroundOne-carbon metabolism in cancer: moonlighting functions of metabolic enzymes and anti-tumor therapy
Cao, X., Guo, Y., Guo, Z., Liu, Y., Dou, Y., & Xue, L. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10308-9 · Cited by 16 · see citing works
Yan, H., Shi, J., Dai, Y., Li, X., Wu, Y., Zhang, J., Gu, Z., Zhang, C., & Leng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02580-4 · Cited by 15 · see citing works
“have found modulating MDSCs in TME may improve the efficacy of EZH2 inhibitors to suppress antitumor immunity [113].”
BackgroundDesign, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer
Le, M.-L., Lu, W., Tan, X., Luo, B., Yu, T., Sun, Y., Guo, Z., Huang, P., Zhu, D., Wu, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01250 · Cited by 15 · see citing works
The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
Wu, S.-Y., Xie, Z., Yan, L.-Y., Liu, X., Zhang, Y., Wang, D., Dong, J., & Sun, H. (2022) · BMC Immunology · doi:10.1186/s12865-022-00502-7 · Cited by 15 · see citing works
Potential therapies targeting nuclear metabolic regulation in cancer
Chen, Y., Xu, J., Liu, X., Guo, L., Yi, P., & Cheng, C. (2023) · MedComm · doi:10.1002/mco2.421 · Cited by 14 · see citing works
- Authors
- Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B.
- Affiliations
- Army Medical University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Long, Haixia
- Zhu, Bo
- Venue
- Cancer Research
- Published
- 2019-04-15
- Volume
- 79
- Issue
- 8
- Pages
- 2009-2020
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2911341716
- Cited by
- 185
- References
- 43
- Citations by year
- 2026: 10 · 2025: 28 · 2024: 28 · 2023: 30 · 2022: 29 · 2021: 29 · 2020: 21 · 2019: 9
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Nature Science Foundation of China (81472648, 81802865, and 81620108023)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- EZH2, GSK126, EZH2 inhibitors, myeloid-derived suppressor cells, antitumor immunity, tumor immune microenvironment, CD4+ T cells, CD8+ T cells, interferon-gamma, Gr-1, hematopoietic progenitor cells, myeloid differentiation, epigenetic regulation, combination therapy
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Myeloid-Derived Suppressor Cells, Animals, Colonic Neoplasms, Female, Humans, Indoles, Mice, Inbred C57BL, Mice, Nude, Pyridones, Tumor Cells, Cultured, Apoptosis, CD8-Positive T-Lymphocytes, Carcinoma, Lewis Lung, Receptors, Chemokine, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
